View ValuationHexima 将来の成長Future 基準チェック /06現在、 Heximaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長42.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Oct 24Hexima Limited, Annual General Meeting, Nov 27, 2025Hexima Limited, Annual General Meeting, Nov 27, 2025. Location: at the offices of qr lawyers, level 6, 400 collins street, melbourne, vic 3000, Australiaお知らせ • Dec 04Real Thing Entertainment cancelled the acquisition of Hexima Limited (ASX:HXL) in a reverse merger transaction.Real Thing Entertainment agreed to acquire Hexima Limited (ASX:HXL) in a reverse merger transaction for AUD 8.1 million on July 24, 2024. As per the transaction, Real Thing Entertainment will issue, 789.7 million shares to the shareholders of Hexima Limited as consideration. also issue up to 25 million shares to two RealThing shareholders to redeem two convertible notes. The proposed acquisition was subject to conditions precedent outlined in the 24 July 2024 announcement, including shareholder approvals and raising capital as part of re-compliance with the ASX Listing Rule Chapter 1 and 2 admission requirements. The transaction is expected to complete on October 9, 2024. On September 27, 2024 Hexima Limited announced the extension to the date for satisfaction of conditions precedent related to the binding but conditional Share Sale Agreement to acquire 100% of the shares of Real Thing Entertainment to December 16, 2024. Real Thing Entertainment cancelled the acquisition of Hexima Limited (ASX:HXL) in a reverse merger transaction on December 3, 2024. The Board is unable to have sufficient confidence that the conditions precedent will be able to be satisfied, including that the requisite level of capital would be able to be raised, or the general meeting arranged to be held and the other re-compliance requirements completed, before the conditions precedent satisfaction date. The Board has formed the view that committing funds to complete the process for calling the general meeting to seek the approvals would not be appropriate in those circumstances. Accordingly, after Board consideration, the Company has given notice of termination of the share sale agreement to RealThing and the vendors in accordance with the provisions of the agreement relating to the conditions precedent.お知らせ • Dec 03Hexima Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 7.5 million.Hexima Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 7.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 375,000,000 Price\Range: AUD 0.02 Transaction Features: Subsequent Direct Listingお知らせ • Oct 29Hexima Limited, Annual General Meeting, Nov 29, 2024Hexima Limited, Annual General Meeting, Nov 29, 2024. Location: at the offices of william buck, level 20, 181 william street, melbourne, vic 3000 Australiaお知らせ • Jul 25Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million.Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 375,000,000 Price\Range: AUD 0.02 Transaction Features: Subsequent Direct ListingBoard Change • Dec 04No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). COO & Director Nicole van der Weerden is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Nov 29Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as DirectorHexima Limited announced that Dr. Nicole van der Weerden has resigned as a director of the company effective 28 November 2023, as she pursues other endeavours.お知らせ • Oct 19Hexima Limited, Annual General Meeting, Nov 28, 2023Hexima Limited, Annual General Meeting, Nov 28, 2023, at 10:00 AUS Eastern Standard Time.お知らせ • Sep 20Hexima Limited Appoints Phillip Hains as A Non-Executive DirectorHexima Limited announced the appointment of Phillip Hains as a Non-Executive Director, effective 18 September 2023. Mr. Hains is a Chartered Accountant with over 30 year experience. Mr. Hains has served the needs of a number of company boards, committees and management.Reported Earnings • Sep 02Full year 2023 earnings released: AU$0.011 loss per share (vs AU$0.066 loss in FY 2022)Full year 2023 results: AU$0.011 loss per share (improved from AU$0.066 loss in FY 2022). Revenue: AU$1.48m (down 74% from FY 2022). Net loss: AU$1.92m (loss narrowed 81% from FY 2022).New Risk • Sep 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.3m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 34% per year over the past 5 years. Market cap is less than US$10m (AU$3.84m market cap, or US$2.49m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$4.8m revenue, or US$3.1m).Recent Insider Transactions • Jun 07Insider recently bought AU$155k worth of stockOn the 5th of June, John Tarrant bought around 13m shares on-market at roughly AU$0.012 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.お知らせ • May 12Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate DirectorHexima Limited announced the resignation of Mr. Steven Skala as an alternate director of the Company, effective 11 May 2023.Reported Earnings • Mar 04First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.029 loss in 1H 2022)First half 2023 results: AU$0.009 loss per share (improved from AU$0.029 loss in 1H 2022). Revenue: AU$1.35m (down 42% from 1H 2022). Net loss: AU$1.55m (loss narrowed 62% from 1H 2022).お知らせ • Dec 22Nicole Van Der Weerden to Step Down as CEO of Hexima LimitedHexima Limited announces that Dr. Nicole van der Weerden, its Acting CEO and former COO, will step down from her executive responsibilities effective 31 December, 2022. Dr. van der Weerden will continue as a Non-Executive Director of the Company and continue to support Hexima through this transition period. This step is consistent with Hexima's previously announced intention to manage expenses associated with non-essential employees in a cost effective and orderly manner. Hexima's operational activities have been largely wound down over the past 6 months, reducing the need for a full-time CEO. The Board continues to advance its stated strategic goal of maximizing shareholder value through a transaction, supported by the Company's contract Company Secretary and contract CFO.お知らせ • Dec 14+ 1 more updateHexima Limited, Annual General Meeting, Jan 31, 2023Hexima Limited, Annual General Meeting, Jan 31, 2023, at 10:00 AUS Eastern Standard Time. Location: the offices of Arnold Bloch Leibler, Level 21, 333 Collins Street Melbourne Australia Agenda: To consider to remove Mr Michael Aldridge as a Director; to consider to remove Mr Jake Nunn as a Director; to consider to remove Mr Scott Robertson as a Director; and to consider appoint Mr Chris Mews as a Director.お知らせ • Dec 05Hexima Limited Announces Board ChangesHexima Limited announced the following board changes: The removal of Mr. Michael Aldridge as a director; The removal of Mr. Jake Nunn as a director; and the removal of Mr. Scott Robertson as a director.Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 5 experienced directors. 1 highly experienced director. 1 independent director (5 non-independent directors). Non-Executive Chairman Jonathan West is the most experienced director on the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Oct 01+ 1 more updateHexima Limited, Annual General Meeting, Nov 16, 2022Hexima Limited, Annual General Meeting, Nov 16, 2022, at 10:00 AUS Eastern Standard Time.Reported Earnings • Aug 31Full year 2022 earnings released: AU$0.066 loss per share (vs AU$0.061 loss in FY 2021)Full year 2022 results: AU$0.066 loss per share (down from AU$0.061 loss in FY 2021). Net loss: AU$10.0m (loss widened 46% from FY 2021). Over the next year, revenue is expected to shrink by 100% compared to a 33% growth forecast for the Biotechs industry in Australia.お知らせ • Aug 02Hexima Limited Announces Management ChangesHexima Limited announced that Mr. Michael Aldridge, its Managing Director & CEO, will resign his executive responsibilities effective immediately. Nicole van der Weerden, currently Chief Operating Officer, will serve as acting CEO. Mr. Aldridge will continue as a non-executive director of the Company. This step is consistent with Hexima's previously announced intention to manage expenses associated with non-essential employees in a cost effective and orderly manner. Mr. Aldridge will not be remunerated for his role as non-executive director.お知らせ • Jul 12Hexima Limited Announces Phase II Results of PezadeftideHexima Limited announced the results of its phase II clinical study of pezadeftide (HXP124) for the treatment of onychomycosis (HXP124-ONY-002). HXP124-ONY-002 was designed and conducted as a phase II, multi-centre, randomized, double-blind, vehicle-controlled study to investigate the efficacy, safety and tolerability of pezadeftide (HXP124) in three dosing cohorts in patients with mild to moderate onychomycosis. Subjects were randomised to receive once daily topical application of 2% (20 mg/mL) pezadeftide or vehicle to all infected toenails in one of three cohorts (randomization 3:1 pezadeftide to vehicle): Cohort 1: 2 treatment periods of 6 weeks; N=29 pezadeftide, 9 vehicle Cohort 2: 2 treatment periods of 6 weeks plus once-weekly maintenance dosing for 23 weeks; N=30 pezadeftide, 10 vehicle Cohort 3: 5 treatment periods of 6 weeks plus 1 treatment period of 1 week; N=30 pezadeftide, 9 vehicle. A total of 117 patients were enrolled; 14 were withdrawn or dropped out prior to completing the study. Patients were assessed for safety and efficacy at scheduled visits (weeks 13, 24, 36) during the course of the study and at the final follow-up visit at week 40. Inclusion and exclusion criteria were generally consistent with those adopted in pivotal clinical studies of the leading branded topical product in the US market. There was a balanced distribution of patients between cohorts according to age, weight, height, and BMI, 80% were male, 20% female and 89% of enrolled patients were Caucasian. Completers were defined as having complied and received 85% or more of drug doses. Pezadeftide was well-tolerated and safe, with only three Serious Adverse Events (fall, angina and depression) reported and none reported as drug-related. Overall, Adverse Events (144) were primarily mild, with no unexpected Treatment Emergent Adverse Events, and were similar in reported and observed for pezadeftide and vehicle-treated patients, regardless of Cohort. The summary of efficacy as at week 40 is shown in the table below. These endpoints are the pre- defined efficacy parameters in the phase II study and are as defined by FDA. There was no consistent effect observed in pezadeftide-treated patients at week 40 compared to vehicle-treated, with the best efficacy results observed in Cohort 2.お知らせ • Jun 24Hexima Limited Announces Preliminary Results of Phase II Clinical Study of PezadeftideOn June 24, 2022, Hexima Limited announced that based on its preliminary review, the results of its phase II clinical study of pezadeftide for the treatment of onychomycosis (HXP124-ONY-002) are inconclusive and will require further detailed investigation and evaluation. The results seen in this study do not appear to correlate with results observed in its prior phase I study (HXP124-ONY-001) and do not support moving directly into a phase III program. Hexima intends to conduct a detailed review of the complete clinical trial data set and study conduct and expects to report its findings when complete.Board Change • Apr 27Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (5 non-independent directors). Non-Executive Chairman Jonathan West is the most experienced director on the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.分析記事 • Mar 21Is Hexima (ASX:HXL) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. By way of example, Hexima...分析記事 • Sep 06Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Reported Earnings • Aug 29Full year 2021 earnings released: AU$0.061 loss per share (vs AU$0.028 loss in FY 2020)Full year 2021 results: Net loss: AU$6.87m (loss widened 90% from FY 2020).お知らせ • Jul 15Hexima Limited Extends Its Patent Protection for PezadeftideHexima Limited announced that a European patent covering the use of pezadeftide for the treatment of onychomycosis will be granted on 14 July 2021. The patent (#3209319) is described as "A Method of Treatment" and provides broad protection covering the therapeutic use of pezadeftide, as well as topical formulations containing pezadeftide, for the treatment of onychomycosis. The patent provides protection until 2035 and Hexima also expects to benefit from up to an additional five years of market exclusivity through the supplementary patent certification available for medicinal products in member states of the European Union. The award of this European patent further strengthens Hexima's patent portfolio which includes similar granted patents in the United States, Japan, Singapore and Australia. Hexima continues to pursue further patent filings in these and other jurisdictions; most recently receiving notification of the grant of "A Method of Treatment" patent (#382906) in Mexico.お知らせ • Apr 27Hexima Limited to Present Clinical Data from its Phase I/IIa Clinical Trial of HXP 124 for the Treatment of Onychomycosis at American Podiatric Medical Association Annual ConferenceHexima Limited announced that it has been selected to present clinical data from its Phase I/IIa clinical trial of HXP 124 for the treatment of onychomycosis at the annual meeting of the American Podiatric Medical Association (APMA) in Aurora, Colorado in July 2021. The APMA represents an important venue for the presentation of HXP124's potential in onychomycosis. Podiatrists are the specialists who tend to manage most cases of onychomycosis and importantly write 80% of all prescriptions for onychomycosis in the US. Onychomycosis is a common fungal nail infection in the nail plate and nail bed. Prevalence of onychomycosis has been estimated at between 10% (Japan) and 13.8% (USA). Onychomycosis is an infectious disease with significant healthcare burden, it causes pain in approximately 50% of patients and in the US results in close to four doctor's visits annually for treatment.[3] Onychomycosis impacts a patient's quality of life with 51% unable to wear the shoes they would prefer and 66% distressed by the appearance of their nail. It is important to treat onychomycosis as the fungi in the nail and can be a source of secondary infection in other areas of the body or infect family members and spread to the environment. Onychomycosis is the most common nail disorder, and the most common skin infection, accounting for 50% of all nail diseases. It is particularly prevalent in older, diabetic and immune compromised populations. The global market for treatments for onychomycosis was approximately USD 3.7 billion in 2018. Approved prescription therapies for onychomycosis comprise either oral or topical medications. Oral medications are associated with adverse effects such as nausea, taste disturbance, and flatulence. They can also severely impact liver function and so often require liver function monitoring. The clinical and commercial success of topical medications has been constrained by an inability of anti-fungal agents to effectively penetrate the human nail and the lack of sufficient anti-fungal activity when in contact with the target pathogen.分析記事 • Mar 02Read This Before Selling Hexima Limited (ASX:HXL) SharesWe've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...お知らせ • Jan 08Hexima Limited Updates Timeline to Phase 2B ResultsHexima Limited developing HXP124, a new prescription treatment for onychomycosis, announced an updated timeline to delivery of results from its phase IIb clinical trial which is being conducted in patients with onychomycosis. The pace of enrolment of patients into the trial, which is being conducted in Australia and New Zealand, has been modestly impacted by State travel restrictions, business closures and mandated lock downs due to the Coronavirus pandemic. These events have not affected in any way the integrity of the trial but are likely to result in data from the clinical trial being available one calendar quarter later than previously anticipated. Hexima has recently added additional clinical investigator sites and adopted other measures to accelerate patient recruitment and enrolment. Accordingly, Hexima expects to announce results of its phase IIb clinical trial of HXP124 in patients with onychomycosis in the second quarter of 2022.お知らせ • Dec 01Hexima Limited has completed an IPO in the amount of AUD 3.280771 million.Hexima Limited has completed an IPO in the amount of AUD 3.280771 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,403,854 Price\Range: AUD 0.2 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Hexima は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測ASX:HXL - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20240-100N/A3/31/20240-1-1-1N/A12/31/20230-1-1-1N/A9/30/20231-1-1-1N/A6/30/20231-2-2-2N/A3/31/20233-5-6-6N/A12/31/20225-8-9-9N/A9/30/20225-9-10-10N/A6/30/20226-10-10-10N/A3/31/20225-9-8-8N/A12/31/20215-8-6-6N/A9/30/20214-8-6-6N/A6/30/20214-7-6-6N/A3/31/20213-6-4-4N/A12/31/20203-5-2-2N/A9/30/20203-4-2-2N/A6/30/20202-4-2-2N/A3/31/20203-4-2-2N/A12/31/20193-4-2-2N/A9/30/20193-3-2-2N/A6/30/20193-3-2-2N/A3/31/20194-2-2-2N/A12/31/20184-2-2-2N/A9/30/20184-2-2-2N/A6/30/20184-2-2-2N/A3/31/20184-2N/A-2N/A12/31/20174-2N/A-2N/A9/30/20174-2N/A-2N/A6/30/20174-2N/A-1N/A3/31/20174-2N/A0N/A12/31/20165-2N/A1N/A9/30/20165-2N/A0N/A6/30/20165-2N/A-1N/A3/31/20165-2N/A-3N/A12/31/20155-1N/A-4N/A9/30/20155-2N/A-3N/A6/30/20155-2N/A-2N/A3/31/20155-2N/A0N/A12/31/20145-3N/A1N/A9/30/20145-2N/A-1N/A6/30/20144-2N/A-3N/A3/31/20144-3N/A-4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: HXLの予測収益成長が 貯蓄率 ( 2.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: HXLの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: HXLの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: HXLの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: HXLの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: HXLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/01/21 13:06終値2024/10/24 00:00収益2024/06/30年間収益2024/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hexima Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Graeme WaldCanaccord Genuity Historic (Wilsons Advisory and Stockbroking Ltd.Shane StoreyCanaccord Genuity Historic (Wilsons Advisory and Stockbroking Ltd.
お知らせ • Oct 24Hexima Limited, Annual General Meeting, Nov 27, 2025Hexima Limited, Annual General Meeting, Nov 27, 2025. Location: at the offices of qr lawyers, level 6, 400 collins street, melbourne, vic 3000, Australia
お知らせ • Dec 04Real Thing Entertainment cancelled the acquisition of Hexima Limited (ASX:HXL) in a reverse merger transaction.Real Thing Entertainment agreed to acquire Hexima Limited (ASX:HXL) in a reverse merger transaction for AUD 8.1 million on July 24, 2024. As per the transaction, Real Thing Entertainment will issue, 789.7 million shares to the shareholders of Hexima Limited as consideration. also issue up to 25 million shares to two RealThing shareholders to redeem two convertible notes. The proposed acquisition was subject to conditions precedent outlined in the 24 July 2024 announcement, including shareholder approvals and raising capital as part of re-compliance with the ASX Listing Rule Chapter 1 and 2 admission requirements. The transaction is expected to complete on October 9, 2024. On September 27, 2024 Hexima Limited announced the extension to the date for satisfaction of conditions precedent related to the binding but conditional Share Sale Agreement to acquire 100% of the shares of Real Thing Entertainment to December 16, 2024. Real Thing Entertainment cancelled the acquisition of Hexima Limited (ASX:HXL) in a reverse merger transaction on December 3, 2024. The Board is unable to have sufficient confidence that the conditions precedent will be able to be satisfied, including that the requisite level of capital would be able to be raised, or the general meeting arranged to be held and the other re-compliance requirements completed, before the conditions precedent satisfaction date. The Board has formed the view that committing funds to complete the process for calling the general meeting to seek the approvals would not be appropriate in those circumstances. Accordingly, after Board consideration, the Company has given notice of termination of the share sale agreement to RealThing and the vendors in accordance with the provisions of the agreement relating to the conditions precedent.
お知らせ • Dec 03Hexima Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 7.5 million.Hexima Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 7.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 375,000,000 Price\Range: AUD 0.02 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 29Hexima Limited, Annual General Meeting, Nov 29, 2024Hexima Limited, Annual General Meeting, Nov 29, 2024. Location: at the offices of william buck, level 20, 181 william street, melbourne, vic 3000 Australia
お知らせ • Jul 25Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million.Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 375,000,000 Price\Range: AUD 0.02 Transaction Features: Subsequent Direct Listing
Board Change • Dec 04No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). COO & Director Nicole van der Weerden is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Nov 29Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as DirectorHexima Limited announced that Dr. Nicole van der Weerden has resigned as a director of the company effective 28 November 2023, as she pursues other endeavours.
お知らせ • Oct 19Hexima Limited, Annual General Meeting, Nov 28, 2023Hexima Limited, Annual General Meeting, Nov 28, 2023, at 10:00 AUS Eastern Standard Time.
お知らせ • Sep 20Hexima Limited Appoints Phillip Hains as A Non-Executive DirectorHexima Limited announced the appointment of Phillip Hains as a Non-Executive Director, effective 18 September 2023. Mr. Hains is a Chartered Accountant with over 30 year experience. Mr. Hains has served the needs of a number of company boards, committees and management.
Reported Earnings • Sep 02Full year 2023 earnings released: AU$0.011 loss per share (vs AU$0.066 loss in FY 2022)Full year 2023 results: AU$0.011 loss per share (improved from AU$0.066 loss in FY 2022). Revenue: AU$1.48m (down 74% from FY 2022). Net loss: AU$1.92m (loss narrowed 81% from FY 2022).
New Risk • Sep 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.3m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 34% per year over the past 5 years. Market cap is less than US$10m (AU$3.84m market cap, or US$2.49m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$4.8m revenue, or US$3.1m).
Recent Insider Transactions • Jun 07Insider recently bought AU$155k worth of stockOn the 5th of June, John Tarrant bought around 13m shares on-market at roughly AU$0.012 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
お知らせ • May 12Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate DirectorHexima Limited announced the resignation of Mr. Steven Skala as an alternate director of the Company, effective 11 May 2023.
Reported Earnings • Mar 04First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.029 loss in 1H 2022)First half 2023 results: AU$0.009 loss per share (improved from AU$0.029 loss in 1H 2022). Revenue: AU$1.35m (down 42% from 1H 2022). Net loss: AU$1.55m (loss narrowed 62% from 1H 2022).
お知らせ • Dec 22Nicole Van Der Weerden to Step Down as CEO of Hexima LimitedHexima Limited announces that Dr. Nicole van der Weerden, its Acting CEO and former COO, will step down from her executive responsibilities effective 31 December, 2022. Dr. van der Weerden will continue as a Non-Executive Director of the Company and continue to support Hexima through this transition period. This step is consistent with Hexima's previously announced intention to manage expenses associated with non-essential employees in a cost effective and orderly manner. Hexima's operational activities have been largely wound down over the past 6 months, reducing the need for a full-time CEO. The Board continues to advance its stated strategic goal of maximizing shareholder value through a transaction, supported by the Company's contract Company Secretary and contract CFO.
お知らせ • Dec 14+ 1 more updateHexima Limited, Annual General Meeting, Jan 31, 2023Hexima Limited, Annual General Meeting, Jan 31, 2023, at 10:00 AUS Eastern Standard Time. Location: the offices of Arnold Bloch Leibler, Level 21, 333 Collins Street Melbourne Australia Agenda: To consider to remove Mr Michael Aldridge as a Director; to consider to remove Mr Jake Nunn as a Director; to consider to remove Mr Scott Robertson as a Director; and to consider appoint Mr Chris Mews as a Director.
お知らせ • Dec 05Hexima Limited Announces Board ChangesHexima Limited announced the following board changes: The removal of Mr. Michael Aldridge as a director; The removal of Mr. Jake Nunn as a director; and the removal of Mr. Scott Robertson as a director.
Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 5 experienced directors. 1 highly experienced director. 1 independent director (5 non-independent directors). Non-Executive Chairman Jonathan West is the most experienced director on the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 01+ 1 more updateHexima Limited, Annual General Meeting, Nov 16, 2022Hexima Limited, Annual General Meeting, Nov 16, 2022, at 10:00 AUS Eastern Standard Time.
Reported Earnings • Aug 31Full year 2022 earnings released: AU$0.066 loss per share (vs AU$0.061 loss in FY 2021)Full year 2022 results: AU$0.066 loss per share (down from AU$0.061 loss in FY 2021). Net loss: AU$10.0m (loss widened 46% from FY 2021). Over the next year, revenue is expected to shrink by 100% compared to a 33% growth forecast for the Biotechs industry in Australia.
お知らせ • Aug 02Hexima Limited Announces Management ChangesHexima Limited announced that Mr. Michael Aldridge, its Managing Director & CEO, will resign his executive responsibilities effective immediately. Nicole van der Weerden, currently Chief Operating Officer, will serve as acting CEO. Mr. Aldridge will continue as a non-executive director of the Company. This step is consistent with Hexima's previously announced intention to manage expenses associated with non-essential employees in a cost effective and orderly manner. Mr. Aldridge will not be remunerated for his role as non-executive director.
お知らせ • Jul 12Hexima Limited Announces Phase II Results of PezadeftideHexima Limited announced the results of its phase II clinical study of pezadeftide (HXP124) for the treatment of onychomycosis (HXP124-ONY-002). HXP124-ONY-002 was designed and conducted as a phase II, multi-centre, randomized, double-blind, vehicle-controlled study to investigate the efficacy, safety and tolerability of pezadeftide (HXP124) in three dosing cohorts in patients with mild to moderate onychomycosis. Subjects were randomised to receive once daily topical application of 2% (20 mg/mL) pezadeftide or vehicle to all infected toenails in one of three cohorts (randomization 3:1 pezadeftide to vehicle): Cohort 1: 2 treatment periods of 6 weeks; N=29 pezadeftide, 9 vehicle Cohort 2: 2 treatment periods of 6 weeks plus once-weekly maintenance dosing for 23 weeks; N=30 pezadeftide, 10 vehicle Cohort 3: 5 treatment periods of 6 weeks plus 1 treatment period of 1 week; N=30 pezadeftide, 9 vehicle. A total of 117 patients were enrolled; 14 were withdrawn or dropped out prior to completing the study. Patients were assessed for safety and efficacy at scheduled visits (weeks 13, 24, 36) during the course of the study and at the final follow-up visit at week 40. Inclusion and exclusion criteria were generally consistent with those adopted in pivotal clinical studies of the leading branded topical product in the US market. There was a balanced distribution of patients between cohorts according to age, weight, height, and BMI, 80% were male, 20% female and 89% of enrolled patients were Caucasian. Completers were defined as having complied and received 85% or more of drug doses. Pezadeftide was well-tolerated and safe, with only three Serious Adverse Events (fall, angina and depression) reported and none reported as drug-related. Overall, Adverse Events (144) were primarily mild, with no unexpected Treatment Emergent Adverse Events, and were similar in reported and observed for pezadeftide and vehicle-treated patients, regardless of Cohort. The summary of efficacy as at week 40 is shown in the table below. These endpoints are the pre- defined efficacy parameters in the phase II study and are as defined by FDA. There was no consistent effect observed in pezadeftide-treated patients at week 40 compared to vehicle-treated, with the best efficacy results observed in Cohort 2.
お知らせ • Jun 24Hexima Limited Announces Preliminary Results of Phase II Clinical Study of PezadeftideOn June 24, 2022, Hexima Limited announced that based on its preliminary review, the results of its phase II clinical study of pezadeftide for the treatment of onychomycosis (HXP124-ONY-002) are inconclusive and will require further detailed investigation and evaluation. The results seen in this study do not appear to correlate with results observed in its prior phase I study (HXP124-ONY-001) and do not support moving directly into a phase III program. Hexima intends to conduct a detailed review of the complete clinical trial data set and study conduct and expects to report its findings when complete.
Board Change • Apr 27Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (5 non-independent directors). Non-Executive Chairman Jonathan West is the most experienced director on the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
分析記事 • Mar 21Is Hexima (ASX:HXL) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. By way of example, Hexima...
分析記事 • Sep 06Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Reported Earnings • Aug 29Full year 2021 earnings released: AU$0.061 loss per share (vs AU$0.028 loss in FY 2020)Full year 2021 results: Net loss: AU$6.87m (loss widened 90% from FY 2020).
お知らせ • Jul 15Hexima Limited Extends Its Patent Protection for PezadeftideHexima Limited announced that a European patent covering the use of pezadeftide for the treatment of onychomycosis will be granted on 14 July 2021. The patent (#3209319) is described as "A Method of Treatment" and provides broad protection covering the therapeutic use of pezadeftide, as well as topical formulations containing pezadeftide, for the treatment of onychomycosis. The patent provides protection until 2035 and Hexima also expects to benefit from up to an additional five years of market exclusivity through the supplementary patent certification available for medicinal products in member states of the European Union. The award of this European patent further strengthens Hexima's patent portfolio which includes similar granted patents in the United States, Japan, Singapore and Australia. Hexima continues to pursue further patent filings in these and other jurisdictions; most recently receiving notification of the grant of "A Method of Treatment" patent (#382906) in Mexico.
お知らせ • Apr 27Hexima Limited to Present Clinical Data from its Phase I/IIa Clinical Trial of HXP 124 for the Treatment of Onychomycosis at American Podiatric Medical Association Annual ConferenceHexima Limited announced that it has been selected to present clinical data from its Phase I/IIa clinical trial of HXP 124 for the treatment of onychomycosis at the annual meeting of the American Podiatric Medical Association (APMA) in Aurora, Colorado in July 2021. The APMA represents an important venue for the presentation of HXP124's potential in onychomycosis. Podiatrists are the specialists who tend to manage most cases of onychomycosis and importantly write 80% of all prescriptions for onychomycosis in the US. Onychomycosis is a common fungal nail infection in the nail plate and nail bed. Prevalence of onychomycosis has been estimated at between 10% (Japan) and 13.8% (USA). Onychomycosis is an infectious disease with significant healthcare burden, it causes pain in approximately 50% of patients and in the US results in close to four doctor's visits annually for treatment.[3] Onychomycosis impacts a patient's quality of life with 51% unable to wear the shoes they would prefer and 66% distressed by the appearance of their nail. It is important to treat onychomycosis as the fungi in the nail and can be a source of secondary infection in other areas of the body or infect family members and spread to the environment. Onychomycosis is the most common nail disorder, and the most common skin infection, accounting for 50% of all nail diseases. It is particularly prevalent in older, diabetic and immune compromised populations. The global market for treatments for onychomycosis was approximately USD 3.7 billion in 2018. Approved prescription therapies for onychomycosis comprise either oral or topical medications. Oral medications are associated with adverse effects such as nausea, taste disturbance, and flatulence. They can also severely impact liver function and so often require liver function monitoring. The clinical and commercial success of topical medications has been constrained by an inability of anti-fungal agents to effectively penetrate the human nail and the lack of sufficient anti-fungal activity when in contact with the target pathogen.
分析記事 • Mar 02Read This Before Selling Hexima Limited (ASX:HXL) SharesWe've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
お知らせ • Jan 08Hexima Limited Updates Timeline to Phase 2B ResultsHexima Limited developing HXP124, a new prescription treatment for onychomycosis, announced an updated timeline to delivery of results from its phase IIb clinical trial which is being conducted in patients with onychomycosis. The pace of enrolment of patients into the trial, which is being conducted in Australia and New Zealand, has been modestly impacted by State travel restrictions, business closures and mandated lock downs due to the Coronavirus pandemic. These events have not affected in any way the integrity of the trial but are likely to result in data from the clinical trial being available one calendar quarter later than previously anticipated. Hexima has recently added additional clinical investigator sites and adopted other measures to accelerate patient recruitment and enrolment. Accordingly, Hexima expects to announce results of its phase IIb clinical trial of HXP124 in patients with onychomycosis in the second quarter of 2022.
お知らせ • Dec 01Hexima Limited has completed an IPO in the amount of AUD 3.280771 million.Hexima Limited has completed an IPO in the amount of AUD 3.280771 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,403,854 Price\Range: AUD 0.2